References
- Braun-Falco O, Plewing G, Wolff HH, Burgdorf WHJr. Dermatitis. In: Braun-Falco O Plewing G Wolff HH Burgdorf WHJr, Dermatology. 2nd ed.. Berlin: Springer-Verlag. 2000; 457–520.
- Odom RB, James WD, Berger TG. Seborrheic dermatitis, psoriasis recalcitrant palmoplantar eruptions, pustular dermatitis, and erythroderma. In: Odom RB James WD Berger TG Andrews' diseases of the skin. 9th ed.. Philadelphia: WB Saunders. 2000; 214–53.
- Gupta AK, Chow M. 2003; Pimecrolimus: A review. J Eur Acad Dermatol Venereol. 17:493–503.
- Miyachi Y, Imamura S, Niwa Y. 1986; Anti-oxidant action of metronidazole: A possible mechanism of action in rosacea. Br J Dermatol. 114:231–4.
- Aizawa H, Michihito N, Kon Y. 1992; Influence of oral metronidazole on the endocrine milieu and sebum excretion rate. J Dermatol. 9:959–63.
- Nielsen PG. 1984; In vitro antifungal effect of metronidazole on Pityrosporum ovale. Mykosen. 27:474–6.
- Koca R, Altinyazar HC, Eştürk E. 2003; Is topical metronidazole effective in seborrhoeic dermatitis? A double-blind study. Int J Dermatol. 42:632–5.
- Ozcan H, Seyhan M, Yologlu S. 2007; Is metronidazole 0.75% gel effective in the treatment of seborrhoeic dermatitis? A double-blind, placebo controlled study. Eur J Dermatol. 17:313–16.
- Parsad D, Pandhi R, Negi KS, Kumar B. 2001; Topical metronidazole in seborrhoeic dermatitis-a double-blind study. Dermatology. 202:35–7.
- Seçkin D, Gurbuz O, Akin O. 2007; Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrhoeic dermatitis: A randomized, double-blind study. J Eur Acad Dermatol Venereol. 21:345–50.
- Grassberger M, Steinhoff M, Schneider D, Luger TA. 2004; Pimecrolimus-An anti-inflammatory drug targeting the skin. Exp Dermatol. 13:721–30.
- Luger T, VanLeent EJM, Graeber M, Hedgecock S, Thurston M, Kandra A, 2001; SDZ ASM 981: An emerging safe and effective treatment of atopic dermatitis. Br J Dermatol. 144:788–94.
- Brownell I, Quan LT, Hsu S. 2003; Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J. 9:13.
- Kim BS, Kim SH, Kim MB, Oh CK, Jang HS, Kwon KS. 2007; Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: An open-label clinical study in Korean patients. J Korean Med Sci. 22:868–72.
- Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. 2004; Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res. 30:191–5.
- Cunha PR. 2006; Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol. 6:69–70.
- Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, 2007; Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 57:257–64.
- Koc E, Arca E, Kose O, Akar A. 2008; An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 1:1–5.
- Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. 2004; Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol. 151:1071–5.
- Gorman CR, White SW. 2004; Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream. Arch Dermatol. 140:457–60.
- Ehst BD, Warshaw EM. 2004; Alcohol-induced application site erythema after topical immunomodulator use and its inhibition by aspirin. Arch Dermatol. 140:1014–15.